Current Protein Identity：P28222
New Search
Difference tags compare only the current result set; every original PDB and assembly record remains separate.
Related-Structure Differences
Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.
| PDB Entry | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Experimental Method | Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 4IAQ Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with dihydroergotamine (PSI Community Target) Deposited 2012-12-07 | Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
33–239（207 aa）
Chain A
304–390（87 aa）
|
Mutation：L138W, M29W, H124I, R128L Mutation：L138W, M29W, H124I, R128L | 2GM Dihydroergotamine × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
Lipid Cubic Phase (LCP)；pH 8.7；293 K；100 mM Tris pH 8.7, 32-36% (v/v) PEG400, 90 mM sodium citrate tribasic dihydrate, 120 mM ammonium sulfate
, Lipid Cubic Phase (LCP), temperature 293K
|
Resolution 2.80 Å R-free 0.257 |
| 4IAR Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with ergotamine (PSI Community Target) Deposited 2012-12-07 | Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–239（207 aa）
Chain A
306–390（85 aa）
|
Mutation：L138W, M29W, H124I, R128L Mutation：L138W, M29W, H124I, R128L | ERM Ergotamine × 1 OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
Lipid Cubic Phase (LCP)；pH 7.5；293 K；100 mM Tris pH 7.5, 30% (v/v) PEG400, 400 mM lithium chloride
, Lipid Cubic Phase (LCP), temperature 293K
|
Resolution 2.70 Å R-free 0.261 |
| 5V54 Crystal structure of 5-HT1B receptor in complex with methiothepin Deposited 2017-03-13 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
37–239（203 aa）
Fragment：UNP residues 37-239,UNP residues 304-390
Chain A
304–390（87 aa）
Fragment：UNP residues 37-239,UNP residues 304-390
Chain B
37–239（203 aa）
Fragment：UNP residues 37-239,UNP residues 304-390
Chain B
304–390（87 aa）
Fragment：UNP residues 37-239,UNP residues 304-390
|
Mutation：L138W Mutation：L138W Mutation：L138W Mutation：L138W | 89F 1-methyl-4-[(5~{S})-3-methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl]piperazine × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100mM Bis-Tris (pH7.0), 155mM Ammonium phosphate monobasic, 26% PEG300, 0.01M GSH (L-Glutathione reduced), GSSG (L-Glutathione oxidized)
|
Resolution 3.90 Å R-free 0.288 |
| 6G79 Coupling specificity of heterotrimeric Go to the serotonin 5-HT1B receptor Deposited 2018-04-05 | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain S
34–390（357 aa）
|
Not recorded | EP5 2-[5-[2-[4-(4-cyanophenyl)piperazin-1-yl]-2-oxidanylidene-ethoxy]-1~{H}-indol-3-yl]ethylazanium × 1 | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.78 Å |
| 7C61 Crystal structure of 5-HT1B-BRIL and SRP2070_Fab complex Deposited 2020-05-21 | Assembly 1 Insufficient information Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain A
33–239（207 aa）
Chain A
306–390（85 aa）
|
Mutation：L138W,M1007W,H1102I,R1106L Mutation：L138W,M1007W,H1102I,R1106L | ERM Ergotamine × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；30% PEG400, 0.4M SODIUM THIOCYANATE, 0.1M SODIUM ACETATE PH 5.5
|
Resolution 3.00 Å R-free 0.290 |